Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer
September 06 2017 - 08:05AM
Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced the appointment of Tom Graney to the role of Senior Vice
President and Chief Financial Officer (CFO). Mr. Graney will begin
his role with Vertex on September 13, 2017 and will report to
Executive Vice President and Chief Operating Officer Ian Smith. Mr.
Graney will be responsible for the development and execution of the
financial strategy and operations that support Vertex’s business
plans, including the Finance, Accounting and Internal Audit
functions. Mr. Graney most recently served as CFO and Senior Vice
President of Finance and Corporate Strategy at Ironwood
Pharmaceuticals.
“As Vertex continues its evolution to a leading global biotech,
it is critical that we continue to build a strong and experienced
leadership team,” said Ian Smith, Executive Vice President and
Chief Operating Officer of Vertex. “Tom has the ideal blend of
financial acumen, leadership skills, and industry experience that
will be important as Vertex grows and expands as a global
company."
“I am thrilled to take on this important role with Vertex, a
company that I have long admired for its unwavering commitment to
patients and to discovering, developing and commercializing
transformative medicines for people with serious and
life-threatening diseases,” said Mr. Graney.
Tom Graney BiographyAt Ironwood Pharmaceuticals, Mr.
Graney was responsible for Finance, Corporate Strategy, Corporate
Development, Quality, Supply Chain, IT, Corporate Communications
and Investor Relations. Prior to joining Ironwood in 2014, he
worked at Johnson & Johnson for approximately 20 years in both
the U.S. and abroad, most recently serving as Worldwide VP of
Finance and CFO for Ethicon Surgical Care.
Mr. Graney serves on the board of directors of AC Immune SA, a
clinical stage Swiss-based biopharmaceutical company focused on
neurodegenerative diseases. He holds a B.S. in accounting from the
University of Delaware and an M.B.A. in marketing, finance and
international business from the Leonard N. Stern School of Business
at New York University.
About VertexVertex is a global biotechnology company that
invests in scientific innovation to create transformative medicines
for people with serious and life-threatening diseases. In addition
to clinical development programs in CF, Vertex has more than a
dozen ongoing research programs focused on the underlying
mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters
is now located in Boston's Innovation District. Today,
the company has research and development sites and commercial
offices in the United
States, Europe, Canada and Australia. Vertex is
consistently recognized as one of the industry's top places to
work, including being named to Science magazine's Top
Employers in the life sciences ranking for seven years in a
row.
For additional information and the latest updates from the
company, please visit www.vrtx.com.
(VRTX-GEN)
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170906005960/en/
Vertex Pharmaceuticals
IncorporatedInvestors:Michael Partridge,
617-341-6108orEric Rojas, 617-961-7205orZach Barber,
617-341-6470orMedia:617-341-6992mediainfo@vrtx.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2023 to Mar 2024